Objective. Chronic regional pain syndrome (CRPS) is a severe pain condition that usually results from an injury or surgical procedure. The pain in CRPS often spreads from the site of injury, and with time becomes refractory to conventional therapy. The present study was undertaken to evaluate the effects of 5-day continuous intravenous lidocaine treatment in patients afflicted with CRPS.
Introduction
C omplex regional pain syndrome (CRPS) usually follows injury to a peripheral nerve, a surgical procedure, or minor trauma. The mechanism of action involves both central and peripheral components of the neuroaxis [1, 2] , as well as interactions between the immune and nervous system [3, 4] . Factor analysis of a large group of CRPS patients has revealed that the signs and symptoms cluster into four distinct subgroups: 1) abnormal pain processing; 2) skin color and temperature changes; 3) edema, vasomotor, and sudomotor abnormalities (hyperhidrosis most frequently); and 4) abnormalities of motor function and trophic changes [5, 6] . The most recent consensus conference panel on CRPS held in Budapest in 2004 proposed that diagnostic criteria for CRPS include one symptom from each of the four factors and one sign in at least two with the provision that there is no other diagnosis that better explains the signs and symptoms [7] . It is clear that the process frequently spreads from the originally injured extremity [8] , and in some patients may encompass a major part of the body. It is also evident in many patients that with time, there is increased intensity of pain and there is centralization of the process. This causes dysregulation of the central nervous system control of autonomic, somatosensory, and motor systems [2, 9] .
Until recently, there have been few therapeutic options for severe longstanding patients that have failed standard therapies [9] [10] [11] . The rational for using systemic lidocaine for CRPS patients is based on both clinical studies and animal models of neuropathic pain. These have demonstrated that following peripheral nerve injury, tetrodotoxinresistant sodium channels on primary nociceptive afferent fibers and small dorsal root ganglia pain transmission neurons are upregulated and undergo significant physiologic changes [12] [13] [14] . Intravenous lidocaine selectively blocks these specific channels and inhibits repetitive depolarization in a use-dependent manner [15] . In neuropathic pain models, intravenous lidocaine has been demonstrated to: 1) produce dose-dependent suppression of allodynia without blocking nerve conduction [16] ; 2) reduce neuropathic pain behavior by increasing the threshold for mechanical allodynia; 3) reduce the discharge rate of injured nociceptive afferent fibers [17] ; and 4) suppress tonic A-delta and C-fiber discharge initiated by acute injury [18] .
In CRPS patients, a 6-week continuous subcutaneous infusion of 10% lidocaine provided significant pain relief [19] . Continuous lidocaine infusion has been found to be effective in burn patients without causing any major side effects [20] . A randomized placebo-controlled trail of intravenous lidocaine for neuropathic pain delivered at 5 mg/kg over 6 hours provided 4-hour pain relief after cessation of the infusion without causing adverse effects [21] . Experimentally induced secondary hyperalgesia in human subjects was decreased by systemic but not by regional administration of lidocaine, which suggests a central mechanism of action [22, 23] .
Systemic administration of local anesthetics in addition to lidocaine in neuropathic pain states have also been shown to provide potent clinical anesthesia and pain relief [24] [25] [26] [27] .
In patients with severe generalized CRPS, who have not responded to conventional therapies, more effective treatment is needed. Intravenous administration of lidocaine has been demonstrated to be effective in both animal models of neuropathic pain and in human studies [21, 28] , which supported its trial in CRPS patients. The purpose of this study is to retrospectively review the results of 5-day continuous intravenous lidocaine administration in a group of refractory CRPS patients that met the International Association for the Study of Pain (IASP) criteria for CRPS [7] .
Methods

Patients
This was a retrospective study of 49 patients who were treated with an intravenous lidocaine protocol that consisted of a gradual upward titration to a blood level of 5 mg/L over a 5-day period unless limited by side effects. All were treated on a standard of care basis, had full information in regard to expected benefits and possible complications, had cardiac clearance, and were fully informed and gave their consent for treatment.
The same attending neurologist (R.J.S.) made the diagnosis, examined the patients on a daily basis, and recorded response to treatment and adverse events. Patient records were reviewed, and data regarding demographics, site of CRPS and consequent signs and symptoms, duration of illness, and response to treatment were obtained ( Table 1) .
The Institutional Review Board of Drexel University College of Medicine approval for review was granted for the period of January 2003 to December 2006.
Inclusion Criteria
Inclusion for intravenous lidocaine treatment was limited to severe, long-standing (>2 years) or fulminantly progressive disease (two patients <4 months and three patients <1 year). All patients met the Budapest 2004 IASP consensus criteria for CRPS [7] . Inclusion was limited to physically healthy patients who fulfilled the American Society of Anesthesiologists Physical Status Classification Class I or II.
CRPS symptomatology had to be present in more than one body quadrant or was spreading rapidly. The average pain intensity had to be at least 5 on the Likert numerical rating pain scale (0 being no pain and 10 the worst pain imaginable). All patients had to have failed standard pharmacological or interventional treatments. Failure was defined as: 1) no response to treatment or; 2) no lasting relief of pain (<2 months); and 3) persistence, recurrence, or progression of the syndrome. Prior to treatment, all patients had a complete workup to rule out other possible causes of their syndrome. This included basic blood and chemical parameters that included collagen vascular disease biomarkers. All patients had EMG, quantitative sensory testing, autonomic sensory testing, magnetic resonance imaging (MRI), myelogram with computed tomography (CT) (if bony entrapment of roots was a possibility), and specific ultrasound 
Exclusion Criteria
Patients with known contraindications such as allergies to lidocaine, seizure disorder, a history of substance or drug abuse, psychiatric illness, or suspected somatoform pain disorder were excluded. The investigators felt that issues concerning monetary gain and or loss due to the patient's medical condition may adversely affect the study, therefore patients with active litigation, compensation, or disability issues related to their CRPS were excluded from this study. Cardiac clearance was obtained by the same cardiologists who evaluate all of our CRPS patients prior to initiation of inpatient treatment and included some or all of the following: 1) 24-hour Holter monitor; 2) routine 12-lead electrocardiogram (EKG); and 3) echocardiogram (ECHO) with ejection fraction determination. Pregnancy was an exclusion factor. During the study, the patients were allowed to continue prescribed medications but were not allowed to start new medications or change the dosage of formerly prescribed medications.
Treatment Protocol
All patients were monitored in a step-down unit. Blood pressure, EKG, and oxygenation were monitored in standard fashion. Lidocaine infusion consisted of 2 g of lidocaine in 250 mL of 5% dextrose in water delivered by continuous infusion at a rate of 7.55 cc/h (60.4 mg/h) over the first 24 hours, 11 cc/h over the next 24 hours, 15 cc on day 3, 18 cc/h on day 4, and 21 cc/h (168.0 mg/h) on day 5. Blood lidocaine levels were obtained daily (Table 5) , and the infusion rate increased only if the blood level was less than 5 mg/L. If the blood lidocaine level was greater than 5 mg/L, the rate of infusion was decreased to the rate used on the previous day. If side affects occurred, drop in blood pressure, cardiac arrhythmia, dysphoria, or dizziness, dosage was decreased or stopped. This 5-day treatment protocol was designed after successful treatment of eight previous patients. These patients responded successfully to a titrated maximal infusion rate of 21 cc/h (168.0 mg/h). Faster infusion rates and longer than 5 days of treatment caused dizziness, dysphoria, and hypotension.
General Procedures
The same investigator (R.J.S.) examined all patients during their infusion. The patients were treated in a step-down unit in which their blood pressure, electrocardiogram, and oxygenation were continuously monitored. Spontaneous pain was rated on a numerical rating scale (NRS: 0-10; 0, no pain to 10, worst pain imaginable).
Dynamic mechano-allodynia was determined in the area of involvement by lightly stroking the skin proximally to distally at the midforearm, quadriceps, and gastrocnemius muscles. Patients were instructed to separate this pain from their spontaneous pain and to rate it on a numerical rating scale of 0-10 (NRS: 0-10). All patients noted a return to their baseline pain level within approximately 2 minutes after each stimulus.
Deep pressure pain was determined by palpation at similar points on the appropriate extremity as obtained for mechano-and thermal allodynia. Joint pain was evaluated by palpation at the first metacarpophalangeal joint of the hand and the first metatarsophalangeal joint of the foot. The patients were instructed to rate the intensity of the evoked pain using the NRS: 0-10 for each stimulus.
Sensitivity to a cool stimulus was assessed by response to the steel handle of a reflex hammer applied at the midforearm, quadriceps, and gastrocnemius muscles. Sensitivity to cold was evaluated at follow-up on a numerical rating scale of 0, no sensitivity, to 4, severe sensitivity (NRS: 0-4). Similarly, muscle weakness, spasm, dystonia, tremor, edema, and hyperhidrosis were evaluated using the same NRS scale of 0-4.
At the end of the protocol, patients were called and their records from follow-up visits were reviewed. They were asked to rate their response to treatment in regard to: 1) overall spontaneous pain intensities; 2) pain to light touch; 3) pain to brushing of the skin; 4) deep muscle pain; 5) joint pain; 6) sensitivity to cold; 7) muscle weakness; 8) muscle spasms; 9) dystonia; 10) tremor; 11) swelling; and 12) sweating. The intervals were 1, 3, and 6 months. All patients were called and queried specifically by one author (M.P.) and examined by the same investigator (R.J.S.).
Patients were asked to enter the average spontaneous pain intensities they suffered at 1, 3, and 6 months after their infusion protocol was completed. The answer was based on NRS as noted above where 0 was "no pain" and 10 the most severe pain "imaginable."
Patients were queried in regards to mechanoallodynia in which skin brushing was perceived as pain and asked: 1) Do you feel pain now or over the last month when touched or lightly brushed?; and 2) Do you feel pain now or within the last month when pressure is applied to a joint? The patients were asked to rate the severity of pain to these parameters at 1, 3, and 6 months. Deep muscle pain and sensitivity to cold over the same time period were similarly evaluated.
The patients were also asked to rate the following parameters: 1) weakness; 2) abnormal hand or foot posture; 3) muscle spasms and tremors; 4) swelling and sweating for the 1-, 3-, and 6-month time periods.
All variables are presented as means Ϯ SDs. The statistical significance of differences between pretreatment and posttreatment variables at 1, 3, and 6 months were determined by paired t-tests. Pearson correlations were used for relating pain intensity to outcome variables. A P < 0.05 was considered significant for all analyses. SPSS version 15 was used for all analyses (SPSS Inc., Chicago, IL).
Results
Forty-nine patients were treated (38 female and 11 male; mean age 42.6 Ϯ 12.5 years, range: 18-61.5 years) ( Table 1 ). All patients suffered severe or rapidly spreading CRPS. This was defined as symptoms and signs of CRPS that spread contiguously from the area of injury, to the opposite extremity or ipsilaterally to other extremity within 3 months to a year. Seven had rapid contiguous spread affecting the entire extremity, three suffered mirror spread to the opposite extremity, and 39 had spread to all extremities with involvement of thorax, head, and back to some degree. All patients were unresponsive to multiple conventional treatments and had failed standard pharmacological and physical therapy (Tables 2 and 3 ).
This study revealed that 76% of patients reported at least a 25% reduction of pain, while 31% had a greater than 50% reduction. Only 24% reported little beneficial effects on pain.
Average overall baseline pain intensity of the cohort (N = 49) was NRS 8.9 Ϯ 1.37. After treatment, a significant reduction of pain intensity was observed at 1, 3, and 6 months (NRS 5.5 Ϯ 2.38 P < 0.001, 7.12 Ϯ 2.29 P < 0.001 and NRS 8.45 Ϯ 1.91, P < 0.05), respectively ( Figure 1) .
The effect of lidocaine infusion on specific pain, motor, and autonomic symptoms is shown in Table 4 .
At baseline, pain to light touch for the cohort was a NRS of 8.02 Ϯ 3.00. A significant reduction of pain was noted at 1 and 3 months (NRS 4.76 Ϯ 3.14 and 6.10 Ϯ 3.27; P < 0.001) respectively. At 6 months, statistically significant decrease of pain to light touch from baseline (NRS 7.61 Ϯ 3.07 P < 0.05) was maintained.
Deep muscle pain at baseline was NRS 9.02 Ϯ 1.39. A statistically significant decrease of this pain was noted at all time periods: at 1 month, NRS 5.57 Ϯ 2.69, and 3 months (NRS 7.02 Ϯ 2.33, P < 0.001), and at 6 months (NRS 8.55 Ϯ 1.54; P < 0.05).
Joint pain at baseline for the 49 patients was NRS 8.12 Ϯ 2.41. A statistically significant reduction of this pain was noted at all time points: at 1 month, NRS of 5.24 Ϯ 2.96; P < 0.001, at 3 months 6.33 Ϯ 2.86; P < 0.001, and at 6 months, a less robust decrease to NRS 7.92 Ϯ 2.49; P < 0.05.
At baseline, sensitivity to cold was moderate to severe for most patients (N = 49) at 3.34 Ϯ 1.37. The scale (NRS: 0-4) utilized was 0 "no sensitivity" to 4 "severe sensitivity." At 1 and 3 months, statistically significant decreases of cold sensitivity were observed NRS 2.04 Ϯ 1.43 and 2.53 Ϯ 1.41; P < 0.001. At 6 months, cold sensitivity had almost returned to baseline for the entire group (NRS 3.26 Ϯ 1.41; P = 0.209).
Muscle weakness of the affected extremity was severe 3.39 Ϯ 1.13 for the entire cohort (N = 49). The scale utilized being 0 "no weakness" and 4 being "severely weak." A statistically significant increase in strength was noted at 1 month (NRS 2.73 Ϯ 1.19; P < 0.001) and at 3 months (NRS 2.96 Ϯ 1.22; P < 0.001), respectively. At 6 months, strength had decreased and returned to baseline for the cohort (NRS 3.35 Ϯ 1.15 with a P = 0.322).
Muscle spasms were severe for the great majority of patient (N = 44/49) and were rated as 3.53 Ϯ 1.04. The scale utilized was 0 "no spasms" to 4 "very severe spasms." A statistically significant reduction in muscle spasms was noted at 1 and 3 months for the entire cohort (NRS 2.55 Ϯ 1.4 and 2.94 Ϯ 1.25, P < 0.001). At 6 months, spasms had returned to baseline for the entire group (NRS 3.47 Ϯ 1.06; P = 0.182).
Utilizing a standard definition of dystonia as an abnormally maintained posture, all of the patients (N = 49) suffered this complication of CRPS in the affected extremity [29] . In the upper extremity, the arm, hand, and fingers were held in flexion. In the lower extremity, the foot was plantar flexed and inverted. The dystonias persisted in sleep and were all accompanied by some parameter of dystrophy and swelling.
Dystonia of the affected extremity or extremities was rated 3.41 Ϯ 0.91 on a scale of 0 "no dystonia" to 4 "very severe dystonia," with no or minimal movement of the affected extremities. A statistically significant decrease in dystonia was noted at 1 and 3 months for all patients (NRS 2.41 Ϯ 1.15 and 2.88 Ϯ 1.05; P < 0.001, respectively). At 6 months, dystonia had returned to baseline (NRS 3.37 Ϯ 0.97 with P = 0.322).
The tremors noted in these patients (N = 49) were minimal and are similar to that described by van Hilten [3] . They occurred in the affected extremity or one of the affected extremities on attempted movement. A significant reduction in tremor was noted from a baseline value of 1.38 Ϯ 1.65 to that reported at 1 and 3 months for all patients (NRS 0.75 Ϯ 1.18: P < 0.001 and 0.92 Ϯ 1.4 P = 0.003). At 6 months, tremor had returned to baseline for the entire cohort (NRS 1.27 Ϯ 1.59 with P = 0.168). At baseline, swelling of the affected extremity or extremities affected all 49 patients. It was rated on a scale of 0 "no swelling" to 4 "severe swelling." At baseline, swelling for the entire group (N = 49) was 3.57 Ϯ 0.82. A statistically significant reduction of swelling was noted at 1 month (NRS 1.88 Ϯ 1.35; P < 0.001) and at 3 months (2.45 Ϯ 1.28; P < 0.001). At 6 months, swelling had returned to baseline (NRS 3.43 Ϯ 0.91, P = 0.07).
Sweating was noted in 36/49 patients (74%). The scale utilized was 0 "no sweating" to 4 "severe sweating." Following treatment, there was a statistically significant decrease in patients with hyperhidrosis at 1 and 3 months (43%, P < 0.001, and 52%, P < 0.004), respectively. At 6 months, the percentage of patients in the group with hyperhidrosis had returned almost to baseline (69%, P = 0.5).
At 1 month, 36 patients had a minimum of 10% improvement in their pain parameters, and 13 patients had less than 10% relief in overall pain. For the patients that did improve, the average length of relief was 3.21 Ϯ 1.73 months (P < 0.001).
Daily blood lidocaine levels are shown in Table 5 . There was no correlation for length of relief with mean lidocaine level or highest measured lidocaine level. The length of relief was moderately and significantly correlated with baseline pain intensity (r = 0.34; P = 0.02). Interestingly, a previous study using acute lidocaine infusion also found that relief was related to initial pain intensity [28] .
Complications
The side effects were mild, and no severe complications were noted. Sixteen of 49 (32.6%) patients had side effects. The mild side effects included nausea (N = 1), fatigue (N = 1), bradycardia (N = 2), tachycardia (N = 1), atrial arrhythmia Clinical parameters, tabulated as mean Ϯ SD, before and at 1, 3, and 6 months following 5 days of intravenous lidocaine infusion. The first four parameters (total pain-joint pain) were rated on an NRS scale of 0-10; the remaining parameters were rated on a 0-4 scale, except increased sweating, which was rated as present or absent and tabulated as percent present. Statistical significance was evaluated with a paired t-test. NRS = numerical rating scale.
(N = 1), and hypotension (N = 2). As soon as cardiac complications were noted, the treatment was stopped. Psychiatric side effects included disorientation (N = 1), euphoria (N = 3), hallucinations and nightmares (N = 1). These complications occurred at a dose of 15-18 cc/h (120-144 mg/h). One patient suffered a seizure, one vertigo, and one suffered blurred vision. All side effects disappeared within 12 hours of cessation of treatment, and no long-term effects were noted in any patient.
Discussion
This retrospective review documents a statistically significant effect of an escalating level of intravenous lidocaine on reducing pain in a group of refractory CRPS patients. At 1 month, pain relief from baseline was robust, dropping 3.37 points on a numeric rating scale of 0 to 10. At 3 months, relief was statistically significant and clinically meaningful. At 6 months, only slight improvement remained for most patients, although there were a few outliers with clinically significant relief (12%). For the entire cohort, pain scores were significantly improved for approximately 3.2 months. During this same 3-month period, there was statistically significant improvement in all pain parameters, which included dynamic and static mechano-allodynia, deep muscle pain, joint pain, and thermal allodynia (cold stimulus). Components of the movement disorder (weakness, spasms, dystonia, and tremor) demonstrated a statistically significant but a much less robust response. Neurogenic edema and hyperhidrosis had a statistical and clinically relevant response for 3 months. In general, by 6 months, CRPS factors had returned to baseline. All CRPS factors were statistically improved for 3 months and were clinically relevant with the intravenous lidocaine protocol [5] . The most profound effect was on thermal and mechanical allodynia. Moderate improvement was seen in the movement disorder [30] . CRPS I may be a subset of neuropathic pain [31, 32] . Recent experimental and clinical studies point to central sensitization of pain transmission neurons by both N-methyl-D-aspartate (NMDA) and immune neuronal interactions as a major mechanism in chronic neuropathic pain [9, [33] [34] [35] [36] .
There are several possible mechanisms that may underlie the significant and lasting effects of prolonged intravenous lidocaine in these severely affected CRPS patients. Nerve injury induces changes in the density and location of tetrodotoxinresistant (TTX-R) sodium channels on sensory neurons, decreases their activation threshold and rate of deactivation, which increases their sodium current. These physiological changes may lead to peripheral nociceptive terminal membrane sensitization [37] . TTX-R sodium channels in rat dorsal root ganglion (DRG) neurons are inhibited by intravenous lidocaine, which may block peripheral sensitization [38] . Peripheral nerve injury may maintain a central hyperexcitable state by continual spontaneous discharge due to an abnormal concentration of sodium channels in the injured nerve trunk or its terminal twigs [39] . Earlier experimental studies in the chronic constriction injury model demonstrated that the release of substance P (SP) evoked by noxious stimuli was coupled to preprotachykinin-1 gene expression in small nociceptive DRG ganglia cells, which peaked with the development of hyperalgesia [40, 41] . Experimental studies suggest that sustained release and increased utilization of SP and related tachykinin peptides may be associated with increased spontaneous electrical discharges in large and small diameter sciatic axons generated by ectopic firing near or within the DRG [42] . A recent study in the spinal nerve L5 and L6 transection model also supports the involvement of substance P and calcitonin gene-related peptide (CGRP) in the development and maintenance of neuropathic pain [43] . Treatment with lidocaine and SP and CGRP antagonists delayed the onset of neuropathic pain by 1-4 days compared with saline control rats [43] . Nerve injury has a physiologic correlate, which is instability of the axon membrane with consequent potential oscillation, which may contribute to the initiation of ectopic firing of nociceptive afferents [44, 45] . Following tissue injury in which small nociceptive afferents are damaged, an inflammatory cascade ensues that is associated with persistent lowfrequency spontaneous discharge of A-delta and C-fiber afferents [46] . Systemic lidocaine suppresses this tonic A-delta and C-fiber afferent barrage [18] . Blockade of this abnormal spontaneous afferent drive from damaged nociceptive afferents by systemic lidocaine may decrease NMDA-mediated central sensitization. However, the nociceptive afferent drive may also induce descending facilitating pain transmission from the rostroventromedial medulla, which may be suppressed by lidocaine [47, 48] . This study and experimental work suggest that lidocaine is particularly effective for tactile allodynia [48] .
Limitations of this study are its retrospective nature with all of the pitfalls of this method. These include: 1) recall bias; 2) nonrandomization, nonblinding; 4) and uncontrolled design. In addition to the limitations noted above, the CRPS patient population studied is not representative of most pain centers, as they are drawn from the entire United States and were longstanding and severe. Strengths of the study are: 1) a single physician examined rated and treated all patients; 2) all patients were seen daily during their treatment and most were followed at regular intervals in the clinic. All of the patients were surveyed by telephone (MP); and 3) all patients met strict IASP 2005 criteria for CRPS [7] . This retrospective study provides evidence that intravenous lidocaine administered in an escalating dose to 5 mg/L under carefully monitored conditions is safe and may decrease many signs and symptoms of severe CRPS. A definitive, large, randomized placebocontrolled multicentered clinical trial is needed to confirm these results.
